Oxidative stress may explain how hypertension is maintained by normal levels of angiotensin II

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 6, 2000, Pages 653-660

  Romero, J C ^a,c   Reckelhoff, J F ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Essential hypertension; Isoprostanes; Nitric oxide; Peroxynitrites

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ENDOTHELIN; ISOPROSTANE; NITRIC OXIDE; PEROXYNITRITE;

ARTERIAL PRESSURE; CONFERENCE PAPER; EXTRACELLULAR SPACE; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; SODIUM INTAKE; VASOCONSTRICTION;

ANIMALIA;

EID: 0033945756     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000600006     Document Type: Conference Paper

References (55)

1. World Health Organization (1999). International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension, 17: 151-183.
2. DeWardener H (1990). The primary role of the kidney and salt intake in the aetiology of essential nypertension. Clinical Science. 79: 193-200.
3. Laragh JH (1984). The meaning of plasma renm measurements: renin and sodium volume-mediated (low renin) forms of vasoconstriction in experimental and human hypertension and in the oedematous states of nephrosis and heart failure. Journal of Hypertension, 1: 141-150.
4. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA. McKinstry DN & Gavras I (1979). Oral angiotensin-converting enzyme inhibitor n long-term treatment of hypertensive patients. Annals of Internal Medicine, 90: 19-23.
5. Nelson EB, Harm SC, Goldberg M, Shahinfar S, Goldberg A & Sweet CS (1995). Clinical profile of the first angiotensm II (AT-1 specific) receptor antagonists. In: Laragh JH & Brenner BM (Editors), Hypertension, Pathophysiology, Diagnosis, and Management. Raven Press, New York.
6. Dickinson CJ, Oxor DM, Lawrence JR & Adelaide MB (1963). A slowly developing pressor response to small concentrations of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension. Lancer, I: 1354-1356.
7. McCubbin JW, DeMoura RS, Page IH & Olmsted F (1965). Arterial hypertension elicited by subpressor amounts of angiotensin. Science, 149: 1394-1395.
8. Lever AF (1993). The fast and the slowly developing presser effect of angiotensin II. In: Ian J, Robertson S & Nicholls MG (Editors), The Renin-Angiotensin System Gower Medical Publishing, London.
9. Munoz JM, Braun-Menendez E, Fasciolo JC & Leloir LJ (1939). Hypertension: The substance causing renal hypertension. Nature, 144: 980-989.
10. Griendling KK & Alexander RW (1994). Cellular mechanisms of angiotensin II action. In: Swales JD (Editor), Textbook of Hypertension. Blackwell Scientific Publishing, Oxford.
11. Ames RP, Borkowski AJ, Sicincki AM & Laragh JH (1965). Prolonged infusions of angiotensin II and norepmephrine and blood pressure, electrolyte balance and aldosterone and cortisol secretion in normal man and in cirrhosis with asctes. Journal of Clinical Investigation, 44: 1171-1186.
12. Brown AJ, Casals-Stenzel J, Gofford S, Lever AJ & Morton JJ (1981). Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. American Journal of Physiology. 241: H381-H388.
13. Haas JA, Krier JD, Bolterman RJ & Romero JC (1999). Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension. 34: 983-986.
14. Bean BL, Brown JJ, Casals Stenzel J, Fraser R, Lever AF, Miller JA, Morton JJ, Fetch B, Riegger AJG, Robertson JIS & Tree M (1979). The relation of arterial pressure and plasma angiotensin II concentration. A change produced by orolonged infusion of angiotensin II in the conscious dog. Circulation Research, 44: 452-458.
15. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Grendling KK & Harrison DG (1996). Angiotensin II-mediated hypertension in the rat increases vascular Superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone Journal of Clinical Investigation, 97: 1916-1923.
16. Pryor WA & Squadrito GL (1995). The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. American Journal of Physiology. 268: L699-L722.
17. Chua BHL, Chua CC, Diglio CA & Siu BB (1993). Regulation of endothelm-1 mRNA by angiotensin II in rat heart endothelial cells. Biochimica et Biophysica Acta, 1178: 201-206.
18. Kohno M, Horio T, Ikeda M, Yokokawa K, Fukui T, Yasunari K, Kurihara N & Takeda T (1992). Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney International, 42: 860-866.
19. Kawaguchi H, Sawa H & Yasuda H (1990). Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary endothelial cells. Journal of Molecular and Cellular Cardiology. 22: 839-842.
20. 2α, m the rat, Journal of Clinical Investigation, 90: 136-141.
21. Fukunaga M, Makita N, Roberts II LJ, Morrow JD, Takahashi K & Badr KF (1993). Evidence for the existence of p2-isoprostane receptors on rat vascular smooth muscle cells. American Journal of Physiology, 264: C1619-C1624.
22. 2-isoprostane, on endothelm-1 release. Journal of Cardiovascular Pharmacology, 26: S51-S52.
23. Michael JR, Markewitz BA & Kohan DE (1997). Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells. American Journal of Physiology. 273: L768-L774.
24. Romero JC, Feldstein AE, Rodriguez-Porce! MG & Cases-Amenos A (1997). New insights into the pathophysiology of renovascular hypertension. Mayo Clinic Proceedings, 72: 251-260.
25. Shanley PF (1996). The pathology of chronic renal ischemia Seminars in Nephrology, 16: 21-32.
26. Kellerman PS (1996). Cellular and metabolic consequences of chronic ischemia on kidney function. Seminars in Nephrology, 16: 33-42.
27. Hennington BS, Zhang H, Miller MT, Granger JP & Reckelhoff JF (1998). Angiotensin II stimulates synthesis of endothelial nitric oxide synthase. Hypertension, 31: 283-288.
28. Boulanger C & Lüscher TF (1990). Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. Journal of Clinical Investigation. 85: 587-590.
29. Saijonmaa O, Ristimaki A & Fyhrquist F (1990). Atrial natriuretic peptide, nitroglycerine, and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells. Biochemical and Biophysical Research Communications, 173: 514-520.
30. Hirata Y, Mtsuoka H, Kimura K, Suygimoto T, Hayakawa H, Suzuki E & Sugimoto T (1991). Role of endothelium-derived relaxing factor in endothelin-mduced renal vasoconstriction. Journal of Cardiovascular Pharmacology, 17: S169-S171.
31. Lerman AJ, Sandok EK, Hildebrand Jr FL & Burrett Jr JC (1992). Inhibition of endothelium-denved relaxing factor enhances endothelin-mediated vasoconstriction. Circulation, 85: 1894-1898.
32. Qui Q, Engles K & Baylis C (1995). Endothelm modulates the presser actions of acute systemic nitric oxide blockade. Journal of the American Society of Nephrology, 6: 1476-1481.
33. Richard V, Hogie M, Clozel M, Löffler B-M & Thuillez C (1995). In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats Circulation, 91: 771-775.
34. Fujita K, Matsumura Y, Miyazaki Y, Takaoka M & Morimoto S (1995). Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase European Journal of Pharmacology. 280: 311-316.
35. Best PJM, Lerman LO, Romero JC, Holmes Jr DR & Lerman A (1999). Chronic endothelm receptor antagonism preserves coronary nitric oxide activity in experimental hypercholesterolemia. Circulation, 99: 1747-1752.
36. Harris PJ, Zhou J, Mendelsohn FAO & Skinner SL (1991), Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats. Journal of Physiology, 433: 25-39.
37. Schnermann J, Lorenz JN, Briggs JP & Keiser JA (1992). Induction of water diuresis by endothelin in rats. American Journal of Physiology, 263: F516-F526.
38. Morrow JD, Harris TM & Roberts II LJ (1990). Noncyclooxygenase oxidative formation of a series of novel prostaglandins analytical ramifications fot measurement of eicosanoids Analytical Biochemistry, 184: 1-10.
39. Pryor WA, Stanley JP & Blair E (1976). Autoxidation of polyunsaturated fatty acids: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipids, 11: 370-379.
40. Morrow JD & Roberts LJ (1997). The isoprostanes: unique bioactive products of lipid peroxidation. Progress in Lipid Research. 36: 1-21.
41. 2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of Sciences. USA, 87: 9383-9387.
42. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts II LJ & Burk RF (1992). Formation of novel non-cyclooxygenase-denved prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. Journal of Clinical Investigation. 90: 2502-2507.
43. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA & Roberts II LJ (1995). Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. New England Journal of Medicine, 332: 1198-1203.
44. Morrow JD, Awad JA, Boss HJ, Blair IA & Roberts II LJ (1992). Non-cyclooxygenasederived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proceedings of the National Academy of Sciences, USA, 89: 10721-10725.
45. Awad JA, Roberts II LJ, Burk RF & Morrow JD (1996). Isoprostanes - prostaglandin-like compounds formed in vivo independently of cyclooxygenase: used as clinical indicators of oxidant damage. Gastroenterology Clinics of North America, 25: 409-427.
46. 2α, is formed in vivo. Biochimica et Biophysics Acta, 1210: 244-248.
47. Reckelhoff JF, Kanji V, Racusen LC, Schmidt AM, Yan SY, Morrow J, Roberts II LJ & Salahudeen AK (1998). Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. American Journal of Physiology. 274: R767-R774.
48. 2α in isolated perfused rat lung. Journal of Applied Physiology. 74: 460-465.
49. 2α, in rabbit lung in situ. American Journal of Physiology. 263: H660-H663.
50. 2-isoprostane, 8-epi-prostaglandin F2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins, 44: 155-163.
51. Guyton AC, Cowley Jr AW, Coleman TG, Liard JF, McCaa RE, Manning Jr RD, Norman Jr RA & Young DB (1973). Pretubular versus tubular mechanisms of renal hypertension. Excerpta Medica International Congress Series No. 302, 15-29.
52. DeClue JW, Guyton AC, Cowley AW, Coleman TG, Norman RA & McCaa RE (1978). Subpressor angiotensin infusions, renal sodium handling and salt-induced hypertension in the dog. Circulation Research. 43: 503-512.
53. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, Ganten D & Sterzel RB (1989). Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension, 14: 396-403.
54. Deng X, Welch WJ & Wilcox CS (1996). Role of nitric oxide in short-term and prolonged effects of angiotensin II on renal hemodynamics. Hypertension, 27: 1173-1179.
55. Schnackenberg CG, Welch WJ & Wilcox CS (1998). Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic. Hypertension, 32: 59-64.